



09-26-02

RCE-1600\$

**REQUEST FOR CONTINUED EXAMINATION (RCE)
TRANSMITTAL****RECEIVED**

SEP 30 2002

TECH CENTER 1600/2900

Address to:

**Commissioner for Patents
Box RCE
Washington, D.C. 20231**

Attorney Docket No. 00-450
Application No. 09/599,087
Filing Date: June 21, 2000
First Named Inventor: Polverino et al.
Group Art Unit: 1642
Examiner Name: S. Rawlings

17
10-3-02**This is a Request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above-identified application.****1. Submission required under 37 C.F.R. § 1.114**

- a. ☐ Previously submitted
i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on August 21, 2002.
ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on
iii. ☐ Other
b. ☒ Enclosed
i. ☒ Amendment/Reply
ii. ☐ Affidavit(s)/Declaration(s)
iii. ☐ Information Disclosure Statement (IDS)
iv. ☐ Other

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17 (i) required)
b. ☐ Other

APPLICATION FEES		
BASIC FEE		\$ 740.00
<input checked="" type="checkbox"/> Extension of Time fee	+\$	\$ 110.00
<input type="checkbox"/> Other	+\$	\$
Total of above calculations =		\$ 850.00
Reduction by 50% for filing by small entity =		\$()
TOTAL =		\$ 850.00

09/27/2002 AWONDAF1 00000110 09599087

01 FC:179

740.00 OP

RCE REQUEST TRANSMITTAL

Attorney Docket No. 00-450

3. ☐ Please charge my Deposit Account No. 13-2490 in the amount of \$.
4. ☒ A check in the amount of \$850.00 is enclosed.
5. The Commissioner is hereby authorized to credit overpayments or charge any additional fees of the following types to Deposit Account No. 13-2490:
- a. ☒ Fees required under 37 CFR 1.16.
 - b. ☒ Fees required under 37 CFR 1.17.
 - c. ☐ Fees required under 37 CFR 1.18.
6. The Commissioner is hereby generally authorized under 37 CFR 1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 CFR 1.53 requiring an extension of time as incorporating a request therefor, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 13-2490 for any fee that may be due in connection with such a request for an extension of time.

7. CERTIFICATE OF MAILING OR TRANSMISSION

☐ I hereby certify that this correspondence is being transmitted by facsimile to the U.S. Patent and Trademark Office at , or being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to :Commissioner for Patents, Box RCE, Washington, DC 20231 on the date indicated below.

☒ I hereby certify that, under 37 CFR § 1.10, I directed that the correspondence identified above be deposited with the United States Postal Service as "Express Mail Post Office to Addressee," addressed to the Commissioner for Patents, Box RCE, Washington, DC 20231, on the date indicated below. Express Mail No. EV214232362US.

8. USPTO CUSTOMER NUMBER**20306**

PATENT TRADEMARK OFFICE

McDonnell Boehnen Hulbert & Berghoff**9. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name	Donald L. Zuhn
Reg. No.	48,710
Signature	
Date	September 25, 2002

RCE (Rev. 11/27/00)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-450)

RECEIVED
SEP 30 2002
TECH CENTER 1600/2900
PATENT

In re Application of: Polverino et al.)

Serial No.: 09/599,087)

Filed: June 21, 2000)

For: Secreted Epithelial Colon Stromal-1)
Molecules and Uses Thereof)

Before the Examiner: S. Rawlings

Group Art Unit: 1642

Commissioner for Patents
Washington, D.C. 20231

Sir:

18/C
60
10-3-2

RESPONSE TO OFFICE ACTION MAILED JUNE 4, 2002

Responsive to the Office Action, mailed June 4, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

AMENDMENTS

The Examiner is respectfully requested to enter the following amendments.

In the Claims:

{ Please amend the following claims: }

1. (Thrice Amended) An isolated nucleic acid molecule comprising a nucleotide sequence:

- (a) as set forth in SEQ ID NO: 4;
(b) of the DNA insert in ATCC Deposit No. PTA-1755;
(c) encoding a polypeptide as set forth in SEQ ID NO: 5; or
(d) complementary to the nucleotide sequence of any of (a) - (c).

2. (Thrice Amended) An isolated nucleic acid molecule comprising a region of the nucleotide sequence of: